Independent intelligence for the laboratory world

Curve Reports Liver Cancer Detection Results for Blood Test

Curve Biosciences reported 77.8% sensitivity and 81.5% specificity for detecting very early hepatocellular carcinoma with a plasma DNA methylation test.

Press release summary

Curve Biosciences reported new performance results for a plasma DNA methylation blood test designed to monitor patients at high risk for hepatocellular carcinoma. The company said its Whole-Body Blood Test detected very early-stage tumors measuring less than 2 centimeters with 77.8% sensitivity and 81.5% specificity.

The test uses artificial-intelligence models trained on Curveโ€™s tissue atlas to analyze disease-associated methylation patterns in cell-free DNA. The results come from a 1,482-patient study conducted across 23 sites. Curve plans to present additional findings at the American Association for the Study of Liver Diseases meeting in November and said the data are being prepared for submission to a peer-reviewed journal.

Why it matters for laboratories

Blood-based surveillance could supplement imaging and established biomarkers for patients with cirrhosis or other high-risk liver conditions, particularly when small tumors are difficult to identify. The reported sensitivity is encouraging for very early disease, but the specificity indicates that confirmatory testing would remain important. The findings have not yet completed peer review, and the announcement does not establish regulatory authorization or routine clinical availability. Laboratories should wait for the full study methods, subgroup results and independent validation before assessing implementation.

Original source: Curve Biosciencesโ€™ Oct. 5, 2026, announcement.

Join the Discussion

Share your experience or ask a question about this article. Please keep comments relevant and respectful.

Leave a Reply

Your email address will not be published. Required fields are marked *